National patterns in imaging utilization for diagnosis of cardiac amyloidosis: A focus on Tc99m-pyrophosphate scintigraphy

Journal of Nuclear Cardiology

Volumn 24, Issue 3, 2017, Pages 1094-1097

  Harb, Serge C ^a   Haq, Muhammad ^b   Flood, Kathleen ^c   Guerrieri, Angela ^c   Passerell, Wendy ^c   Jaber, Wael A ^a   Miller, Edward J ^d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c American Society of Nuclear Cardiol   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cardiac amyloidosis; National survey; Tc99m pyrophosphate

Indexed keywords

PYROPHOSPHATE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CARDIAC IMAGING; CARDIOLOGIST; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR PARAMETERS; ECHOCARDIOGRAPHY; HEALTH CARE UTILIZATION; HEART AMYLOIDOSIS; HEART SCINTISCANNING; HEART TO CONTRALATERAL LUNG RATIO; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; CARDIOMYOPATHY; CLINICAL PRACTICE; DIAGNOSTIC IMAGING; FAMILIAL AMYLOID POLYNEUROPATHY; FEMALE; MALE; MIDDLE AGED; PREVALENCE; UNITED STATES; UTILIZATION; UTILIZATION REVIEW;

AMYLOID NEUROPATHIES, FAMILIAL; CARDIOMYOPATHIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PRACTICE PATTERNS, PHYSICIANS'; PREVALENCE; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M PYROPHOSPHATE; UNITED STATES; UTILIZATION REVIEW;

EID: 84961677886     PISSN: 10713581     EISSN: 15326551     Source Type: Journal    
DOI: 10.1007/s12350-016-0478-3     Document Type: Article

References (7)

1. Jacobson DR, Pastore R, Pool S, Malendowicz S, Kane I, Shivji A, et al. Revised transthyretin Ile 122 allele frequency in African-Americans. Hum Genet 1996;98:236–8.
2. Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation 2012;126:1286–300.
3. Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2014;2:113–22.
4. González-López E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015;36:2585–97.
5. Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46:1076.
6. Rapezzi C, Quarta CC, Guidalotti PL, Pettinato C, Fanti S, Leone O, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging 2011;4:659.
7. Bokhari S, Castaño A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 2013;6:195.